Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Blocking IL-6 signaling prevents astrocyte-induced neurodegeneration in an iPSC-based model of Parkinson’s disease
Meritxell Pons-Espinal, … , Angel Raya, Antonella Consiglio
Meritxell Pons-Espinal, … , Angel Raya, Antonella Consiglio
Published February 8, 2024
Citation Information: JCI Insight. 2024;9(3):e163359. https://doi.org/10.1172/jci.insight.163359.
View: Text | PDF
Research Article Inflammation Neuroscience

Blocking IL-6 signaling prevents astrocyte-induced neurodegeneration in an iPSC-based model of Parkinson’s disease

  • Text
  • PDF
Abstract

Parkinson’s disease (PD) is a neurodegenerative disease associated with progressive death of midbrain dopamine (DAn) neurons in the substantia nigra (SN). Since it has been proposed that patients with PD exhibit an overall proinflammatory state, and since astrocytes are key mediators of the inflammation response in the brain, here we sought to address whether astrocyte-mediated inflammatory signaling could contribute to PD neuropathology. For this purpose, we generated astrocytes from induced pluripotent stem cells (iPSCs) representing patients with PD and healthy controls. Transcriptomic analyses identified a unique inflammatory gene expression signature in PD astrocytes compared with controls. In particular, the proinflammatory cytokine IL-6 was found to be highly expressed and released by PD astrocytes and was found to induce toxicity in DAn. Mechanistically, neuronal cell death was mediated by IL-6 receptor (IL-6R) expressed in human PD neurons, leading to downstream activation of STAT3. Blockage of IL-6R by the addition of the FDA-approved anti–IL-6R antibody, Tocilizumab, prevented PD neuronal death. SN neurons overexpressing IL-6R and reactive astrocytes expressing IL-6 were detected in postmortem brain tissue of patients at early stages of PD. Our findings highlight the potential role of astrocyte-mediated inflammatory signaling in neuronal loss in PD and pave the way for the design of future therapeutics.

Authors

Meritxell Pons-Espinal, Lucas Blasco-Agell, Irene Fernandez-Carasa, Pol Andrés-Benito, Angelique di Domenico, Yvonne Richaud-Patin, Valentina Baruffi, Laura Marruecos, Lluís Espinosa, Alicia Garrido, Eduardo Tolosa, Michael J. Edel, Manel Juan Otero, José Luis Mosquera, Isidre Ferrer, Angel Raya, Antonella Consiglio

×

Figure 5

IL-6/IL-6R signaling is increased in the SNc in postmortem brains at early stages of PD.

Options: View larger image (or click on image) Download as PowerPoint
IL-6/IL-6R signaling is increased in the SNc in postmortem brains at ear...
(A) Representative immunohistochemical sections of the mesencephalon including the substantia nigra pars compacta from control and PD cases at early (Braak stages 1–3) and late stages (Braak stages 4 and 5) of the disease. IL-6 (visualized with DAB) is present in astrocytes (GFAP+ cells; nickel). Scale bar: 25 μm. Images on the upper right show a magnification of the area boxed in the main images. Scale bar: 10 μm. (B) Percentage of GFAP+ cells expressing IL-6 over total GFAP+ cells. (C) IL-6R (green) is localized in DAn in PD cases (Braak stage 2) as visualized by TH immunofluorescence (red); autofluorescence is blocked by preincubating the sections with Sudan black. Scale bar: 100 μm. Asterisks show colocalization of TH+ cells expressing IL-6R. (D) Representative immunofluorescence images showing increased IL-6R immunoreactivity in PD substantia nigra pars compacta (Braak stage 2) as compared with controls. Scale bar: 25 μm. Asterisks show neurons with IL-6R expression. (E) Percentage of IL-6R+ staining area per image/total image area. Postmortem brain samples include: 3 healthy donors, 1 PD (Braak stage 1), 2 PD (Braak stage 2), 2 PD (Braak stage 3), 1 PD (Braak stage 4), and 2 PD (Braak stage 5). We counted 50 astrocytes per individual (GFAP+) from 6–8 images each. One-way ANOVA was used with Bonferroni as post hoc. Student t test was used when only 2 groups were compared. **P < 0.01; ***P < 0.001.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts